Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

GR Life Style
国锐生活

GR LIFE STYLE COMPANY LIMITED
國銳生活有限公司
(Incorporated in Hong Kong with limited liability)
(Stock Code: 108)

(1) RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR; (2) APPOINTMENT OF DIRECTORS; AND (3) CHANGE OF COMPOSITION OF BOARD COMMITTEES

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (the "**Board**") of directors (the "**Director(s)**") of GR Life Style Company Limited (the "**Company**") hereby announces that, Mr. Leung Louis Ho Ming ("**Mr. Leung**") has tendered his resignation as an independent non-executive Director with effect from 13 July 2026 due to his other business commitment. Mr. Leung will cease to be (i) a member of each of the audit committee of the Company (the "**Audit Committee**") and the nomination committee of the Company (the "**Nomination Committee**"); and (ii) the chairman of the remuneration committee of the Company (the "**Remuneration Committee**") with effect from the same day.

Mr. Leung has confirmed that he has no disagreement with the Board, nor is there any matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**").

The Board would like to take this opportunity to express its sincere gratitude to Mr. Leung for his valuable contribution to the Company during his tenure.

APPOINTMENT OF DIRECTORS

The Board hereby announces that Mr. Chen Henan ("**Mr. Chen**") has been nominated as an executive Director and vice chairman (the "**Vice-Chairman**") of the Board, with effect from 13 July 2026. Mr. Liu Bingyang ("**Mr. Liu**") has been nominated as an executive Director, with effect from 13 July 2026. Mr. Huang Yining ("**Mr. Huang**") has been nominated as an independent non-executive Director, with effect from 13 July 2026.

Biographical details of those Directors are set out below:

Biographical details of Mr. Chen

Mr. Chen, aged 40, has been appointed as an executive Director and Vice-chairman, with effect from 13 July 2026. Mr. Chen graduated from Renmin University of China (中國人民大學). Currently, Mr. Chen is one of the executive directors of Beijing Chun Yu Tian Xia Software Co., Ltd.* (北京春雨天下軟件有限公司), an indirectly non wholly-owned subsidiary of the Company. Mr. Chen has extensive experience in management, operations and startup investment in the medical and education sectors, as well as substantial expertise in the Company's strategic investment planning, mergers and acquisitions, asset management and internal control.

Mr. Chen previously served as an industry analyst at China Securities Co., Ltd. (中信建投證券股份有限公司) and as assistant general manager of TFTR Investment Co., Ltd. (天風天睿投資股份公司), where Mr. Chen was primarily engaged in medical industry investment and strategic management. Since 2020, Mr. Chen has been the vice president and general manager of the investment department of Choya Education Group (卓雅教育集團), a technology-driven industrial group focusing on K12 education and higher education.

As at the date of this announcement, Mr. Chen has entered into a letter of appointment with the Company for an initial fixed term of one year commencing from 13 July 2026, which may be terminated by either party serving on the other not less than three months' written notice, subject to retirement by rotation and re-election at least once a year in accordance with the articles of association of the Company and the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**"). Pursuant to his letter of appointment, Mr. Chen will not be entitled to any remuneration at this stage until further review and approval of directors' emolument by the Remuneration Committee and the Board, which is and will be determined with reference to his background, experiences, duties and responsibilities with the Group and the prevailing market conditions.

As at the date of this announcement, save as disclosed herein, Mr. Chen has not held any directorship in any other listed companies the securities of which are listed on any securities market in Hong Kong or overseas in the past three years. Mr. Chen also does not hold any other position with the Company or other members of the Group, nor does he have any other relationship with any Director, senior management, substantial shareholder or controlling shareholder (as defined under the Listing Rules) of the Company. At the date of this announcement, Mr. Chen does not have any interests in the securities of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Biographical details of Mr. Liu

Mr. Liu, aged 52, has been appointed as an executive Director, with effect from 13 July 2026. Mr. Liu graduated from Dongbei University of Finance and Economics (東北財經大學) with a postgraduate degree and holds a double master's degree in business administration and international finance. Mr. Liu has over 25 years of senior management experience in China's top tier of private enterprises, accumulating extensive practical experience and multiple successful cases in capital operations, industrial investment and hard technology, with profound industry insight and comprehensive corporate management capabilities.

Mr. Liu is currently the vice president of Duofu International Investment Group (多弗國際投資集團) and the president of Duofu High-tech Group* (多弗高科集團), and also serves as a director of CHTC Helon Co., Ltd. (恒天海龍股份有限公司) (a company listed on the Shenzhen Stock Exchange, stock code: 000677.SZ). Duofu International Investment Group (多弗國際投資集團) is a leading largescale private enterprise group in China, having been listed among the Top 500 Chinese Enterprises and the Top 500 Private Enterprises for many consecutive years, and holds two listed companies: CHTC Helon Co., Ltd. (恒天海龍股份有限公司) (stock code: 000677.SZ) and Man Sang International Limited (民生國際有限公司) (stock code: 00938.HK).

Mr. Liu previously served at Sany Group (三一集團) as assistant president and concurrently as deputy general manager of Sany Heavy Industry Co., Ltd. (三一重工股份有限公司); thereafter, Mr. Liu served as vice president at Gome Holdings Group (國美控股集團), during which he concurrently acted as chairman of Beijing Centergate Technologies (Holding) Co., Ltd. (北京中關村科技發展(控股)股份有限公司) (listed on the Shenzhen Stock Exchange, stock code: 000931.SZ), executive director of Sunbase International (Holdings) Limited (新恒基國際(集團)有限公司), and director of Tus-Holdings Co., Ltd. (啟迪控股股份有限公司); subsequently, Mr. Liu served as vice president of Zhengbang Group Co., Ltd. (正邦集團有限公司) and concurrently as president of Zhengbang Finance* (正邦金融); Mr. Liu also served as executive vice president of Dongxu Group Co., Ltd. (東旭集團有限公司) and concurrently as chairman of Shanghai Challenge Textile Co., Ltd. (上海嘉麟傑紡織品股份有限公司) (listed on the Shenzhen Stock Exchange, stock code: 002486.SZ).

As at the date of this announcement, Mr. Liu has entered into a letter of appointment with the Company for an initial fixed term of one year commencing from 13 July 2026, which may be terminated by either party serving on the other not less than three months' written notice, subject to retirement by rotation and re-election at least once a year in accordance with the articles of association of the Company and the Listing Rules. Pursuant to his letter of appointment, Mr. Liu will not be entitled to any remuneration at this stage until further review and approval of directors' emolument by the Remuneration Committee and the Board, which is and will be determined with reference to his background, experiences, duties and responsibilities with the Group and the prevailing market conditions.

As at the date of this announcement, save as disclosed herein, Mr. Liu has not held any directorship in any other listed companies the securities of which are listed on any securities market in Hong Kong or overseas in the past three years. Mr. Liu also does not hold any other position with the Company or other members of the Group, nor does he have any other relationship with any Director, senior management, substantial shareholder or controlling shareholder (as defined under the Listing Rules) of the Company. At the date of this announcement, Mr. Liu does not have any interests in the securities of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Biographical details of Mr. Huang

Mr. Huang, aged 70, has been appointed as an independent non-executive Director, with effect from 13 July 2026. Mr. Huang has also been appointed as a member of each of the Audit Committee, the Nomination Committee and Remuneration Committee with effect from the same day. Mr. Huang is a chief physician, professor and doctoral supervisor. Mr. Huang graduated from Peking Union Medical College (北京協和醫學院) with a master's degree in 1987 and undertook advanced training in neurology at Salpêtrière Hospital in Paris, France.

Mr. Huang has over 30 years of experience in clinical practice, teaching and research, with profound expertise in cerebrovascular diseases, difficult neurological disorders and neurosonology. From 1984 to 2002, Mr. Huang worked at the Department of Neurology of Peking Union Medical College Hospital (北京協和醫院), serving successively as resident doctor, attending doctor, associate chief physician and chief physician. Since 2003, Mr. Huang has been the Chief of the Department of Neurology at Peking University First Hospital (北京大學第一醫院). Mr. Huang has led a number of major national research projects, including the National 10th Five-Year Key Project, the National 11th Five-Year Major Special Project, the Ministry of Health Clinical Major Special Project, and the National Natural Science Foundation of China. Mr. Huang has published many high-impact academic papers in top international journals, and his academic achievements have been widely cited. Mr. Huang has extensive industry influence and professional authority, which can provide authoritative expert support for the Company's strategic planning, technical assessment and compliance governance in the healthcare sector.

As at the date of this announcement, Mr. Huang has entered into a letter of appointment with the Company for an initial fixed term of one year commencing from 13 July 2026, which may be terminated by either party serving on the other not less than three months' written notice, subject to retirement by rotation and re-election at least once a year in accordance with the articles of association of the Company and the Listing Rules. Mr. Huang is entitled to an annual directors' fee of HK$120,000, which is determined by the Board based on the recommendation by the Remuneration Committee, with reference to his experience, his duties and responsibilities in the Company as well as the prevailing market condition.

As at the date of this announcement, save as disclosed herein, Mr. Huang has not held any directorship in any other listed companies the securities of which are listed on any securities market in Hong Kong or overseas in the past three years. Mr. Huang also does not hold any other position with the Company or other members of the Group, nor does he have any other relationship with any Director, senior management, substantial shareholder or controlling shareholder (as defined under the Listing Rules) of the Company. At the date of this announcement, Mr. Huang does not have any interests in the securities of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Mr. Huang confirmed that he has satisfied the independence criteria as stipulated in Rule 3.13 of the Listing Rules.

Save as disclosed herein, there is no matter relating to the appointment of Mr. Chen, Mr. Liu and Mr. Huang that needs to be brought to the attention of the holders of securities of the Company, nor is there any information as required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

The Board would like to take this opportunity to welcome Mr. Chen, Mr. Liu and Mr. Huang in joining the Company.

CHANGE OF COMPOSITION OF BOARD COMMITTEES

Upon (i) the appointment of Mr. Chen as an executive Director and Vice-chairman; (ii) the appointment of Mr. Liu as an executive Director; (iii) the appointment of Mr. Huang as an independent non-executive Director; and (iv) the resignation of Mr. Leung as an independent non-executive Director taking effect from 13 July 2026, Ms. To Tsz Wan Vivien has been appointed as the chairman of the Remuneration Committee with effect from 13 July 2026.

By order of the Board
GR Life Style Company Limited
Wei Chunxian
Chairman

Hong Kong, 13 July 2026

As at the date of this announcement, the executive directors of the Company are Mr. Wei Chunxian, Mr. Wei Laier, Mr. Sun Zhongmin, Mr. Chen Henan and Mr. Liu Bingyang; and the independent non-executive directors of the Company are Mr. Tung Woon Cheung Eric, Ms. To Tsz Wan Vivien and Mr. Huang Yining.

* *The English names of Chinese entities marked with "*" are translations of their Chinese names and are included for identification purpose only, and should not be regarded as their official English translation. In the event of any inconsistency, the Chinese name prevails.*